Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Therapeutics (RAPT) over the last 7 years, with Dec 2024 value amounting to $122.3 million.

  • Therapeutics' Net Cash Flow rose 2080.35% to $131.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.3 million, marking a year-over-year increase of 1332.89%. This contributed to the annual value of $122.3 million for FY2024, which is 1332.89% up from last year.
  • Therapeutics' Net Cash Flow amounted to $122.3 million in FY2024, which was up 1,332.89% from $8.5 million recorded in FY2023.
  • Therapeutics' 5-year Net Cash Flow high stood at $122.3 million for FY2024, and its period low was -$52.5 million during FY2020.
  • Its 3-year average for Net Cash Flow is $48.6 million, with a median of $14.9 million in 2022.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 486.20% in 2020, then spiked by 1,774.41% in 2022.
  • Therapeutics' Net Cash Flow (Yearly) stood at -$52.5 million in 2020, then spiked by 98.30% to -$891,000 in 2021, then spiked by 1,774.41% to $14.9 million in 2022, then slumped by 42.81% to $8.5 million in 2023, then soared by 1,332.89% to $122.3 million in 2024.